Kowa Company, Ltd.
https://www.kowa.co.jp/eng/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Kowa Company, Ltd.
Emergex Goes To Battle Against ‘The Nasties’
Emerging Company Profile: The eight-year-old vaccine firm is planning clinical trials in the Philippines and Brazil to see how its synthetic viral peptide vaccine technology stands up against coronaviruses and dengue fever.
Novartis Looks To Maintain A Lead In Radiopharmaceuticals With Mariana Takeout
The acquisition of Mariana will complement Novartis’s lutetium-based radioligand therapies with candidates using actinium. Lilly, Bristol and AstraZeneca all have made recent high-priced buys in the space.
Asia Deal Watch: Ono Inks Partnerships With Switzerland’s Numab, US Biotech Shattuck
Plus alliances involving Xyphos/Kelonia, Nippon Shinyaku/Vicor, Telix/QSAM, Nicox/Kowa, Kyowa Kirin/BridgeBio, as well as deals in brief.
Finance Watch: Scion Life Sciences Launches With $310m Inaugural VC Fund
Private Company Edition: Scion’s first fund exceeded its initial $250m fundraising goal. Also, The Column Group’s incubator raised a $400m-plus fund and Seroba’s fourth fund reaches $134m, while Neurona raised a $120m financing and Cour closed a $105m series A round.
Company Information
- Industry
- Diversified
-
Pharmaceuticals
- OTC, Consumer
-
Medical Devices
- Diagnostic Equipment & Supplies
- Implantable Devices
- Other Names / Subsidiaries
-
- ProEthic Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice